On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus.
Liquid error (templates/article line 15): Error in tag 'section' - 'article-faq-template' is not a valid section type
Back to FAQ
Spin to win Spinner icon